Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of runcaciguat versus placebo in non-proliferative diabetic retinopathy
NL-OMON54177Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic retinopathy (DR) and nonproliferative diabetic retinopathy (NPDR) comparing runcaciguat with placebo (2 arms). Primary endpoint: DRSS improvement of at least 2 steps at 48 weeks. Started Jun 2022; status: recruiting.
02
Drugs
runcaciguat
03
Conditions
diabetic retinopathy (DR)nonproliferative diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on NL-OMON54177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54177.